BL22


Also found in: Wikipedia.

BL22

A 63-kDa anti-CD22 recombinant immunotoxin, containing truncated Pseudomonas exotoxin and variable domains from an anti-CD22 antibody. It was effective against hairy cell leukaemia in phase-II trials of patients who had relapse less than 4 years after cladribine therapy.
References in periodicals archive ?
Bergeron et al., "Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia," The New England Journal of Medicine, vol.
Browning still offers their slick little BL22 and Marlin at least catalogs a 24-inch barreled Model 39A (which at this writing seems to be unavailable).
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
A genetically engineered drug known as BL22 has sent a type of cancer called hairy cell leukemia into full remission in 11 of 16 patients, a study shows.
The findings, reported in the July 26 NEW ENGLAND JOURNAL OF MEDICINE, suggest that BL22 may become a treatment for this type of leukemia.
The other three had their cancer recur within 16 months of being treated with BL22 but then were successfully treated again, Kreitman says.